| 18th Aug 2022 12:01 pm |
EQS |
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate |
| 5th Jul 2022 12:01 pm |
EQS |
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech |
| 22nd Jun 2022 9:05 pm |
EQS |
CureVac Announces Voting Results of General Meeting |
| 8th Jun 2022 9:10 pm |
EQS |
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform |
| 8th Jun 2022 9:05 pm |
EQS |
CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen |
| 25th May 2022 12:06 pm |
EQS |
CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update |
| 25th May 2022 12:01 pm |
EQS |
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development |
| 28th Apr 2022 12:01 pm |
EQS |
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update |
| 22nd Apr 2022 12:01 pm |
EQS |
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022 |
| 21st Apr 2022 12:01 pm |
EQS |
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study |
| 11th Apr 2022 12:01 pm |
EQS |
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government |
| 30th Mar 2022 12:01 pm |
EQS |
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV |
| 1st Mar 2022 12:01 pm |
EQS |
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R) |
| 10th Feb 2022 12:01 pm |
EQS |
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK |
| 17th Jan 2022 12:01 pm |
EQS |
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry |
| 18th Nov 2021 9:11 pm |
EQS |
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update |
| 18th Nov 2021 9:11 pm |
EQS |
CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2021 und informiert über das laufende Geschäft |
| 18th Nov 2021 10:43 am |
EQS |
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine |
| 18th Nov 2021 10:43 am |
EQS |
CureVac veröffentlicht in „Nature' präklinische Daten des COVID-19-Kandidaten der zweiten Generation, CV2CoV, die vergleichbaren Antikörperspiegel wie bei lizenziertem mRNA-Impfstoff nachweisen |
| 10th Nov 2021 12:01 pm |
EQS |
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response |
| 10th Nov 2021 12:01 pm |
EQS |
CureVac präsentiert Daten auf SITC Konferenz aus Phase-1-Studie von Onkologie-Kandidat CV8102, die systemische Immunantwort zeigen |
| 12th Oct 2021 12:03 pm |
EQS |
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology |
| 12th Oct 2021 12:03 pm |
EQS |
CureVac verlagert Fokus der COVID-19-Impfstoffentwicklung auf mRNA-Technologie der zweiten Generation |
| 14th Sep 2021 12:20 pm |
RNS |
CureVac verschlankt europäisches Netzwerk zur mRNA-Produktherstellung |
| 14th Sep 2021 12:20 pm |
RNS |
CureVac Streamlines European Network for mRNA Product Manufacturing |
| 31st Aug 2021 12:00 pm |
EQS |
CureVacs Phase 2b/3-Studiendaten für CVnCoV auf Pre-Print-Server The Lancet veröffentlicht |
| 31st Aug 2021 12:00 pm |
EQS |
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet |
| 30th Aug 2021 12:00 pm |
EQS |
CureVac-Studie: Präklinische Daten zeigen deutliche Verminderung von Leberfibrose mit mRNA-Therapeutikum |
| 30th Aug 2021 12:00 pm |
EQS |
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic |
| 16th Aug 2021 12:11 pm |
EQS |
CureVac veröffentlicht Finanzergebnisse des zweiten Quartals und ersten Halbjahres 2021 und informiert über seine Geschäftsentwicklung |
| 16th Aug 2021 12:11 pm |
EQS |
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update |
| 16th Aug 2021 12:00 pm |
EQS |
CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study |
| 16th Aug 2021 12:00 pm |
EQS |
CureVac : mRNA-basierter COVID-19-Impfstoffkandidat der zweiten Generation, CV2CoV, zeigt verbesserte Immunantwort und Schutzwirkung in präklinischer Studie |
| 30th Jun 2021 9:30 pm |
EQS |
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 |
| 30th Jun 2021 9:30 pm |
EQS |
CureVacs Daten der finalen Analyse der Phase 2b/3-Studie für CVnCoV, den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren |
| 30th Jun 2021 12:00 pm |
EQS |
CureVac gibt Ernennung von Dr. Malte Greune zum Chief Operating Officer und den Funktionswechsel von Dr. Florian von der Mülbe zur beschleunigten Weiterentwicklung des The RNA Printer(R) bekannt |
| 30th Jun 2021 12:00 pm |
EQS |
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R) |
| 24th Jun 2021 9:15 pm |
EQS |
CureVac Announces Voting Results of General Meeting |
| 24th Jun 2021 9:15 pm |
EQS |
CureVac Announces Voting Results of General Meeting (English only) |
| 23rd Jun 2021 12:30 pm |
EQS |
CureVac Provides Supervisory Board Update |
